TCGA-33-A4WN-01A-11R-A262-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 60
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.500
- E2F_TARGETS+0.470
- MYC_TARGETS_V1+0.460
- G2M_CHECKPOINT+0.450
- OXIDATIVE_PHOSPHORYLATION+0.450
- MTORC1_SIGNALING+0.390
- MITOTIC_SPINDLE+0.330
- CHOLESTEROL_HOMEOSTASIS+0.310
- PI3K_AKT_MTOR_SIGNALING+0.250
- UNFOLDED_PROTEIN_RESPONSE+0.250
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.540
- INTERFERON_GAMMA_RESPONSE-0.520
- IL6_JAK_STAT3_SIGNALING-0.500
- INFLAMMATORY_RESPONSE-0.460
- ALLOGRAFT_REJECTION-0.440
- ANGIOGENESIS-0.440
- TNFA_SIGNALING_VIA_NFKB-0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- COAGULATION-0.370
- COMPLEMENT-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-LA-A446-01A-21R-A24Z-07 | — | cohortSQ2 | 0.931 |
| 2 | TCGA-60-2722-01A-01R-0851-07 | — | cohortSQ2 | 0.924 |
| 3 | TCGA-94-8490-01A-11R-2326-07 | — | cohortSQ2 | 0.911 |
| 4 | TCGA-58-A46N-01A-11R-A24H-07 | — | cohortSQ2 | 0.908 |
| 5 | TCGA-46-3768-01A-01R-0980-07 | — | cohortSQ2 | 0.907 |
| 6 | TCGA-33-4532-01A-01R-1201-07 | — | cohortSQ2 | 0.907 |
| 7 | TCGA-77-8143-01A-11R-2247-07 | — | cohortSQ1 | 0.905 |
| 8 | TCGA-4Z-AA7S-01A-11R-A39I-07 | — | — | 0.902 |
| 9 | e235012b-4b29-478a-abad-6a70cd949cfa | — | — | 0.902 |
| 10 | TCGA-77-6845-01A-11R-1949-07 | — | cohortSQ2 | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.450 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.160 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |